Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks-Reference-Cited by-同舟云学术

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks

Published:2022-10-17 Issue:12 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Chen Xi‐Bei¹,Zheng Yu‐Xin¹,Ye Li‐Ran¹,Chen Xue‐Yan¹,Man Xiao‐Yong¹^ORCID

Affiliation:

1. Department of Dermatology Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China

Funder

National Natural Science Foundation of China

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15911

Reference24 articles.

1. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

2. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

3. Secukinumab: First Global Approval

4. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial

5. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice;Experimental Dermatology;2023-07-20